Flt1 peptide-hyaluronate conjugate micelle-like nanoparticles encapsulating genistein for the treatment of ocular neovascularization

Acta Biomaterialia

Volumn 8, Issue 11, 2012, Pages 3932-3940

  Kim, Hyemin ^a   Choi, Jun Sub ^b   Kim, Ki Su ^a   Yang, Jeong A ^a   Joo, Choun Ki ^b   Hahn, Sei Kwang ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Corneal neovascularization; Diabetic retinopathy; Flt1 peptide; Genistein; Hyaluronate

Indexed keywords

AMINO ACIDS; BIOACTIVITY; CONTROLLED DRUG DELIVERY; ENDOTHELIAL CELLS; HYALURONIC ACID; NANOPARTICLES; PEPTIDES; RATS; TARGETED DRUG DELIVERY;

CORNEAL NEOVASCULARIZATION; DIABETIC RETINOPATHY; FLT1 PEPTIDE; GENISTEIN; HYALURONATE; IN-VITRO; NEO-VASCULARIZATION; RECEPTOR-1; SYNTHESISED; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR;

FLAVONOIDS;

GENISTEIN; HYALURONIC ACID; SILVER NITRATE; VASCULOTROPIN RECEPTOR 1; ANGIOGENESIS INHIBITOR; NANOPARTICLE; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CELL PROLIFERATION; CONJUGATE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DIABETIC RETINOPATHY; DRUG EFFECT; DYNAMIC LIGHT SCATTERING; EYE DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LIGHT SCATTERING; MALE; MICELLE; NANOENCAPSULATION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OCULAR NEOVASCULARIZATION; OXYGEN-INDUCED RETINOPATHY; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; TRANSMISSION ELECTRON MICROSCOPY; UMBILICAL VEIN ENDOTHELIAL CELL; ZETA POTENTIAL; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; HUMAN; MOLECULAR GENETICS; PARTICLE SIZE; PATHOLOGY; PERMEABILITY; RETINA; ULTRASTRUCTURE;

RATTUS;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; CORNEAL NEOVASCULARIZATION; DIABETIC RETINOPATHY; GENISTEIN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYALURONIC ACID; MALE; MICELLES; MICROSCOPY, ELECTRON, TRANSMISSION; MOLECULAR SEQUENCE DATA; NANOPARTICLES; PARTICLE SIZE; PEPTIDES; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84873941177     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2012.07.016     Document Type: Article

References (32)

1. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003;2:347-60. (Pubitemid 37361705)
2. Burda C, Chen X, Narayanan R, El-Sayed MA. Chemistry and properties of nanocrystals of different shapes. Chem Rev 2005;105:1025-102. (Pubitemid 40600877)
3. Park JH, Kim JH, Park K, Kim K, Kwon IC. Polymeric nanomedicine for cancer therapy. Prog Polym Sci 2008;33:113-37. (Pubitemid 350278530)
4. Takae S, Miyata K, Oba M, Ishii T, Nishiyama N, Itaka K, et al. PEG-detachable polyplex micelles based on disulfide-linked block catiomers as bioresponsive nonviral gene vectors. J Am Chem Soc 2008;130:6001-9. (Pubitemid 351620847)
5. Kim BS, Park SW, Hammond PT. Hydrogen-bonding layer-by-layer-Assembled biodegradable polymeric micelles as drug delivery vehicles from surfaces. ACS Nano 2008;2:386-92. (Pubitemid 351585956)
6. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol Rev 2001;53:283-318. (Pubitemid 32476118)
7. Nasongkla N, Bey E, Ren J, Ai H, Khemtong C, Guthi JS, et al. Multifunctional polymeric micelles as cancer-targeted. MRI-ultrasensitive drug delivery systems. Nano lett 2006;6:2427-30. (Pubitemid 46076928)
8. Qin S, Geng Y, Discher DE, Yang S. Temperature-controlled assembly and release from polymer vesicles of poly(ethylene oxide)-block- poly(Nisopropylacrylamide). Adv Mater 2006;18:2905-9. (Pubitemid 44759500)
9. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145-60. (Pubitemid 40282557)
10. Etrych T, Jelinkova M, Rihova B, Ulbrich K. New HPMA Copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J Control Release 2001;73:89-102. (Pubitemid 32406104)
11. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006;6:688-701. (Pubitemid 44286001)
12. Oh EJ, Park K, Choi JS, Joo CK, Hahn SK. Synthesis, characterization, and preliminary assessment of anti-Flt1 peptide-hyaluronate conjugate for the treatment of corneal neovascularization. Biomatierlas 2009;30:6026-34.
13. Oh EJ, Choi JS, Kim H, Joo CK, Hahn SK. Anti-Flt1 peptide-hyaluronate conjugate for the treatment of retinal neovascularization and diabetic retinopathy. Biomaterials 2011;32:3115-23.
14. Bae DG, Kim TD, Li G, Yoon WH, Chae CB. Anti-Flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis. Clin Cancer Res 2005;11:2651-61. (Pubitemid 40569466)
15. Gerecht S, Burdick JA, Ferreira LS, Townsend SA, Langer R, Vunjak-Novakovic G. Hyaluronic acid hydrogel for controlled self-renewal and differentiation of human embryonic stem cells. Proc Natl Acad Sci 2007;104:11298-303. (Pubitemid 47175135)
16. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005;5:526-42. (Pubitemid 40942829)
17. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, et al. Regulation of lung injury and repair by toll-like receptors and hyaluronan. Nat Med 2005;11:1173-9. (Pubitemid 43093664)
18. Varghese OP, Sun W, Hilborn J, Ossipov DA. In situ cross-linkable high molecular weight hyaluronan-biophosphonate conjugate for localized delivery and cell-specific targeting: A hydrogel linked prodrug approach. J Am Chem Soc 2009;131:8781-3.
19. Oh EJ, Park K, Kim KS, Kim J, Yang JA, Kong JH, et al. Target specific and longacting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Control Release 2010;141:2-12.
20. Liu Z, Jiao Y, Wang Y, Zhou C, Zhang Z. Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliver Rev 2008;60:1650-62.
21. Gurny R, Ibrahim H, Aebi A, Buri P, Wilson CG, Washington N, et al. Design and evaluation of controlled release systems for the eye. J Control Release 1987;6:367-73. (Pubitemid 18019091)
22. Saettone MF, Chetoni P, Torracca MT, Burgalassi S, Giannaccini B. Evaluation of muco-Adhesive properties and in vivo activity of ophthalmic vehicles based on hyaluronic acid. Int J Pharm 1989;51:203-12. (Pubitemid 19117685)
23. Gadgeel SM, Ali S, Philip PA, Wozniak A, Sarkar FH. Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines. Cancer 2009;115:2165-76.
24. Nakanishi C, Toi M. Nuclear factor-jB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005;5:297-309. (Pubitemid 40488635)
25. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006;71:1397-421.
26. Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 2005;23:1295-311. (Pubitemid 46202288)
27. Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R, et al. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci 1993;90:2690-4. (Pubitemid 23113482)
28. Ibrahim AS, El-Shishtawy MM. JR, Liou GI. Genistein attenuates retinal inflammation associated with diabetes by targeting of microglial activation. Mol Vis 2010;16:2033-42.
29. Wang B, Zou Y, Li H, Yan H, Pan JS, Yuan ZL. Genistein inhibited retinal neovascularization and expression of vascular endothelial growth factor and hypoxia inducible factor 1a in a mouse model of oxygen-induced retinopathy. J Ocul Pharmacol Ther 2005;21:107-13. (Pubitemid 40577965)
30. Oh EJ, Kim JW, Kong JH, Ryu SH, Hahn SK. Signal transduction of hyaluronic acid-peptide conjugate for formyl peptide receptor like 1 receptor. Bioconjug Chem 2008;19:2401-8.
31. Supko JG, Philips LR. High-performance liquid chromatographic assay for genistein in biological fluids. J Chromatogr B 1995;666:157-67.
32. NIH publication No. 85-23, revised in 1985.